SLCO2A1 and malignant colon neoplasm: Indeed, OATP2A1 expression in vascular endothelial cells coupled with our in vitro studies showing that angiogenesis is suppressed in HUVECs by OATP2A1 inhibition strongly supports this as a potential pharmacological target to improve colon cancer outcomes.